Ⅱ期结肠癌的辅助化学治疗  

Adjuvant chemotherapy of stage Ⅱ colon cancer

作　　者：曹建[1] 孙萍[1] 

机构地区：[1]青岛大学医学院附属烟台毓璜顶医院肿瘤内二科,青岛264000

出　　处：《国际肿瘤学杂志》2013年第6期463-465,共3页Journal of International Oncology

摘　　要：Ⅱ期结肠癌术后是否需行辅助化疗，目前尚存争议。有研究表明，高危Ⅱ期结肠癌能从术后辅助化疗中获益。在临床病理特征方面，T4期、有穿孔和肿瘤周围淋巴管或血管浸润等的Ⅱ期结肠癌患者能从含有奥沙利铂的辅助化疗中获益；在基因分子水平方面，Ⅱ期结肠癌高微卫星不稳定性（MSI-H）表达较多，且不能从氟尿嘧啶化疗中获益，而染色体18q杂合子丢失（18qLOH）、Cx43及基因表达谱等在辅助化疗中的指导作用尚无定论，需进一步研究。For stage Ⅱ colon cancer patients after surgery, the benefit of adjuvant chemotherapy remains controversial. Several studies indicate that the patients with high-risk stage Ⅱ colon cancer can benefit from adjuvant chemotherapy after surgery. According to the clinical and pathological features, the stage Ⅱ colon cancer patients including T4 lesion, perforation, peritumoral lymphovascular invasion can benefit from the adjuvant chemotherapy of oxaliplatin. In the horizontal of molecular and genetic levels, the stage Ⅱ colon cancer patients can express high microsatellite instability （MSI-H） and cannot benefit from the chemotherapy of Fluorouracil. The guiding functions of 18q loss of heterozygosity （ 18q LOH）, Cx43 and gene expression profi- ling in adjuvant chemotherapy are still unclear, and need further study.

关 键 词：结肠肿瘤 微卫星不稳定性 杂合子丢失 

分 类 号：R735[医药卫生—肿瘤]